کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
2820579 | 1160865 | 2015 | 7 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Methylation status at HYAL2 predicts overall and progression-free survival of colon cancer patients under 5-FU chemotherapy
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
موضوعات مرتبط
علوم زیستی و بیوفناوری
بیوشیمی، ژنتیک و زیست شناسی مولکولی
ژنتیک
پیش نمایش صفحه اول مقاله
![عکس صفحه اول مقاله: Methylation status at HYAL2 predicts overall and progression-free survival of colon cancer patients under 5-FU chemotherapy Methylation status at HYAL2 predicts overall and progression-free survival of colon cancer patients under 5-FU chemotherapy](/preview/png/2820579.png)
چکیده انگلیسی
DNA methylation variations in gene promoter regions are well documented tumor-specific alterations in human malignancies including colon cancer, which may influence tumor behavior and clinical outcome. As a subset of colon cancer patients does not benefit from adjuvant chemotherapy, predictive biomarkers are desirable. Here, we describe that DNA methylation levels at CpG loci of hyaluronoglucosaminidase 2 (HYLA2) could be used to identify stage II and III colon cancer patients who are most likely to benefit from 5-flourouracil (5-FU) chemotherapy with respect to overall survival and progression-free survival.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Genomics - Volume 106, Issue 6, December 2015, Pages 348–354
Journal: Genomics - Volume 106, Issue 6, December 2015, Pages 348–354
نویسندگان
Katrin Pfütze, Axel Benner, Michael Hoffmeister, Lina Jansen, Rongxi Yang, Hendrik Bläker, Esther Herpel, Alexis Ulrich, Cornelia M. Ulrich, Jenny Chang-Claude, Hermann Brenner, Barbara Burwinkel,